162 related articles for article (PubMed ID: 24040330)
1. Glutathione S-transferase T1, O1 and O2 polymorphisms are associated with survival in muscle invasive bladder cancer patients.
Djukic TI; Savic-Radojevic AR; Pekmezovic TD; Matic MG; Pljesa-Ercegovac MS; Coric VM; Radic TM; Suvakov SR; Krivic BN; Dragicevic DP; Simic TP
PLoS One; 2013; 8(9):e74724. PubMed ID: 24040330
[TBL] [Abstract][Full Text] [Related]
2. GSTA1, GSTM1, GSTP1, and GSTT1 polymorphisms and susceptibility to smoking-related bladder cancer: a case-control study.
Matic M; Pekmezovic T; Djukic T; Mimic-Oka J; Dragicevic D; Krivic B; Suvakov S; Savic-Radojevic A; Pljesa-Ercegovac M; Tulic C; Coric V; Simic T
Urol Oncol; 2013 Oct; 31(7):1184-92. PubMed ID: 24075358
[TBL] [Abstract][Full Text] [Related]
3. Glutathione S-transferase M1 and T1 polymorphisms: susceptibility and outcomes in muscle invasive bladder cancer patients.
Kang HW; Song PH; Ha YS; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Moon SK; Kim WJ
Eur J Cancer; 2013 Sep; 49(14):3010-9. PubMed ID: 23810248
[TBL] [Abstract][Full Text] [Related]
4. Association of genetic polymorphism of glutathione S-transferase (GSTM1, GSTT1, GSTP1) with bladder cancer susceptibility.
Safarinejad MR; Safarinejad S; Shafiei N; Safarinejad S
Urol Oncol; 2013 Oct; 31(7):1193-203. PubMed ID: 22154357
[TBL] [Abstract][Full Text] [Related]
5. The
Pavlovic D; Ristic S; Djukanovic L; Matic M; Kovacevic M; Pljesa-Ercegovac M; Hadzi-Djokic J; Savic-Radojevic A; Djukic T
Medicina (Kaunas); 2023 Jan; 59(1):. PubMed ID: 36676788
[TBL] [Abstract][Full Text] [Related]
6. GSTO1*C/GSTO2*G haplotype is associated with risk of transitional cell carcinoma of urinary bladder.
Djukic T; Simic T; Radic T; Matic M; Pljesa-Ercegovac M; Suvakov S; Coric V; Pekmezovic T; Novakovic I; Dragicevic D; Savic-Radojevic A
Int Urol Nephrol; 2015 Apr; 47(4):625-30. PubMed ID: 25716313
[TBL] [Abstract][Full Text] [Related]
7. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
[TBL] [Abstract][Full Text] [Related]
8. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.
Deng X; Yang X; Cheng Y; Liu X; Li X; Zhao R; Qin C; Lu Q; Yin C
Sci Rep; 2015 Sep; 5():14000. PubMed ID: 26354850
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy.
Funke S; Timofeeva M; Risch A; Hoffmeister M; Stegmaier C; Seiler CM; Brenner H; Chang-Claude J
Pharmacogenomics; 2010 Jan; 11(1):33-41. PubMed ID: 20017670
[TBL] [Abstract][Full Text] [Related]
10.
Baba SM; Pandith AA; Shah ZA; Geelani SA; Bhat JR; Gul A; Guru SA; El-Serehy HA; Koul AM; Mansoor S
Front Oncol; 2021; 11():714421. PubMed ID: 34722260
[TBL] [Abstract][Full Text] [Related]
11. GSTT1 as a prognosticator for recurrence and progression in patients with non-muscle-invasive bladder cancer.
Ha YS; Yan C; Lym MS; Jeong P; Kim WT; Kim YJ; Yun SJ; Lee SC; Moon SK; Choi YH; Kim WJ
Dis Markers; 2010; 29(2):81-7. PubMed ID: 21045267
[TBL] [Abstract][Full Text] [Related]
12. Glutathione S-Transferase Gene Polymorphisms and Treatment Outcome in Cervical Cancer Patients under Concomitant Chemoradiation.
Abbas M; Kushwaha VS; Srivastava K; Banerjee M
PLoS One; 2015; 10(11):e0142501. PubMed ID: 26571237
[TBL] [Abstract][Full Text] [Related]
13. GSTM1 tissue genotype as a recurrence predictor in non-muscle invasive bladder cancer.
Ha YS; Yan C; Jeong P; Kim WT; Yun SJ; Kim IY; Moon SK; Kim WJ
J Korean Med Sci; 2011 Feb; 26(2):231-6. PubMed ID: 21286014
[TBL] [Abstract][Full Text] [Related]
14. Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients.
Sreeja L; Syamala V; Hariharan S; Syamala VS; Raveendran PB; Sivanandan CD; Madhavan J; Ankathil R
J Exp Ther Oncol; 2008; 7(1):73-85. PubMed ID: 18472644
[TBL] [Abstract][Full Text] [Related]
15. The prognostic impact of GSTM1/GSTP1 genetic variants in bladder Cancer.
Albarakati N; Khayyat D; Dallol A; Al-Maghrabi J; Nedjadi T
BMC Cancer; 2019 Oct; 19(1):991. PubMed ID: 31646988
[TBL] [Abstract][Full Text] [Related]
16. Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients.
Ott K; Lordick F; Becker K; Ulm K; Siewert J; Höfler H; Keller G
Int J Colorectal Dis; 2008 Aug; 23(8):773-82. PubMed ID: 18443805
[TBL] [Abstract][Full Text] [Related]
17. Associations of GSTM1*0 and GSTA1*A genotypes with the risk of cardiovascular death among hemodialyses patients.
Suvakov S; Damjanovic T; Pekmezovic T; Jakovljevic J; Savic-Radojevic A; Pljesa-Ercegovac M; Radovanovic S; Simic DV; Pljesa S; Zarkovic M; Mimic-Oka J; Dimkovic N; Simic T
BMC Nephrol; 2014 Jan; 15():12. PubMed ID: 24423050
[TBL] [Abstract][Full Text] [Related]
18. Copy number variation in glutathione-S-transferase T1 and M1 predicts incidence and 5-year survival from prostate and bladder cancer, and incidence of corpus uteri cancer in the general population.
Nørskov MS; Frikke-Schmidt R; Bojesen SE; Nordestgaard BG; Loft S; Tybjærg-Hansen A
Pharmacogenomics J; 2011 Aug; 11(4):292-9. PubMed ID: 20514077
[TBL] [Abstract][Full Text] [Related]
19. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment.
Sweeney C; Ambrosone CB; Joseph L; Stone A; Hutchins LF; Kadlubar FF; Coles BF
Int J Cancer; 2003 Mar; 103(6):810-4. PubMed ID: 12516103
[TBL] [Abstract][Full Text] [Related]
20. The association between polymorphisms in glutathione S-transferase (GSTM1 and GSTT1) and lung cancer outcome.
Gonlugur U; Pinarbasi H; Gonlugur TE; Silig Y
Cancer Invest; 2006; 24(5):497-501. PubMed ID: 16939958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
